Journal of Movement Disorders

Original Article

Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect: Amina Nasri, Ikram Sghaier, Anis Neji, Alya Gharbi, Youssef Abida, Saloua Mrabet, Amina Gargouri, Mouna Ben Djebara, Imen Kacem, Riadh Gouider; J Mov Disord. 2024;17(2):158-170. Published online January 30, 2024; DOI: https://doi.org/10.14802/jmd.23178

1,626 View
86 Download
1 Web of Science
1 Crossref

Objective
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder encompassing several phenotypes with various motor and cognitive deficits. We aimed to study motor and cognitive characteristics across PSP phenotypes and to assess the influence of apolipoprotein E (APOE) gene variants on PSP phenotypic expression.
Methods
In this 20-year cross-sectional study, we retrospectively reviewed the charts of all patients classified as PSP patients and recategorized them according to phenotype using the Movement Disorder Society criteria (2017). Phenotypes were divided into three subgroups, Richardson’s syndrome (PSP-RS), PSP-cortical (PSP with predominant frontal presentation [PSP-F] + PSP with predominant speech/language disorder [PSP-SL] + PSP with predominant corticobasal syndrome [PSP-CBS]) and PSP-subcortical (PSP with predominant parkinsonism [PSP-P] + PSP with progressive gait freezing [PSP-PGF] + PSP with predominant postural instability [PSP-PI] + PSP with predominant ocular motor dysfunction [PSP-OM] + PSP with cerebellar ataxia [PSP-C] + PSP with primary lateral sclerosis [PSP-PLS]), based on clinical presentation during the first 3 years after symptom onset, which defines the early disease stage. Clinical and neuropsychological assessment data were collected. Genotyping of APOE was performed using restriction fragment length polymorphism polymerase chain reaction and verified by Sanger sequencing.
Results
We included 112 PSP patients comprising 10 phenotypes classified into 48 PSP-RS, 34 PSP-cortical (PSP-CBS, 17.6%; PSP-F, 9.4%; PSP-SL, 8.2%) and 30 PSP-subcortical (PSP-P, 11.6%; PSP-PI, 8%; PSP-OM, 2.7%; PSP-PGF, 1.8%; PSP-C, 1.8%; PSP-PLS, 0.9%) subgroups. PSP-RS patients were older at disease onset (p = 0.009) and had more akinetic-rigid and levodopa-resistant parkinsonism (p = 0.006), while PSP-cortical patients had more tremors and asymmetric and/or levodopa-responsive parkinsonism (p = 0.025). Cognitive domains were significantly less altered in the PSP-subcortical subgroup. Overall, PSP-APOEε4 carriers developed parkinsonism earlier (p = 0.038), had earlier oculomotor dysfunction (p = 0.052) and had more altered cognitive profiles. The APOEε4 allele was also associated with a younger age of parkinsonism onset in the PSP-RS phenotype group (p = 0.026).
Conclusion
This study demonstrated the wide phenotypic spectrum of PSP among Tunisians. Disease onset and akinetic-rigid and levodopa-resistant parkinsonism were the hallmarks of the PSP-RS phenotype, while milder cognitive impairment was characteristic of the PSP-subcortical subgroup. The APOEε4 allele was associated with earlier parkinsonism and oculomotor dysfunction and seemed to play a role in defining a more altered cognitive profile in PSP patients.

Citations

Citations to this article as recorded by

Clinical and molecular predictors of survival among atypical parkinsonian syndromes in a North African tertiary referral center
Ikram Sghaier, Amina Nasri, Amal Atrous, Youssef Abida, Alya Gharbi, Amira Souissi, Saloua Mrabet, Mouna Ben Djebara, Imen Kacem, Amina Gargouri-Berrechid, Riadh Gouider
Journal of the Neurological Sciences.2024; 464: 123155. CrossRef

Review Article

Clinical Approach to Progressive Supranuclear Palsy: Helen Ling; J Mov Disord. 2016;9(1):3-13. Published online January 25, 2016; DOI: https://doi.org/10.14802/jmd.15060

35,979 View
1,308 Download
51 Web of Science
47 Crossref

Abstract PDF

Sixty years ago, Steele, Richardson and Olszewski designated progressive supranuclear palsy (PSP) as a new clinicopathological entity in their seminal paper. Since then, in addition to the classic Richardson’s syndrome (RS), different clinical phenotypic presentations have been linked with this four-repeat tauopathy. The clinical heterogeneity is associated with variability of regional distribution and severity of abnormal tau accumulation and neuronal loss. In PSP subtypes, the presence of certain clinical pointers may be useful for antemortem prediction of the underlying PSP-tau pathology. Midbrain atrophy on conventional MRI correlates with the clinical phenotype of RS but is not predictive of PSP pathology. Cerebrospinal fluid biomarkers and tau ligand positron emission tomography are promising biomarkers of PSP. A multidisciplinary approach to meet the patients’ complex needs is the current core treatment strategy for this devastating disorder.

Citations

Citations to this article as recorded by

PSP-Richardson syndrome mimics: An overview and pragmatic approach
J. Necpál, M. Borsek, B. Jeleňová
Revue Neurologique.2024; 180(1-2): 12. CrossRef
Concomitant Medications for Progressive Supranuclear Palsy
Jay M. Iyer, Douglas Gunzler, Anthony E. Lang, Lawrence I. Golbe, Alexander Pantelyat, Adam L. Boxer, Anne-Marie Wills
JAMA Neurology.2024; 81(3): 295. CrossRef
Existing statistical measures and techniques in detecting and evaluating progressive supranuclear palsy, its phenotypes by using MRI modalities: A Review
Nirmal Adam Sait, J Kathirvelan
Materials Today: Proceedings.2023; 80: 2000. CrossRef
The role of magnetic resonance imaging in the diff erential diagnosis of Parkinson’s disease
A. A. Tappakhov, T. E. Popova
Russian neurological journal.2023; 28(1): 5. CrossRef
Clinical features of progressive supranuclear palsy
Yafei Wen, Qijie Yang, Bin Jiao, Weiwei Zhang, Jingyi Lin, Yuan Zhu, Qian Xu, Hui Zhou, Ling Weng, Xinxin Liao, Yafang Zhou, Junling Wang, Jifeng Guo, Xinxiang Yan, Hong Jiang, Beisha Tang, Lu Shen
Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Mechanisms linking cerebrovascular dysfunction and tauopathy: Adding a layer of epiregulatory complexity
Yoon A. Kim, Marian Mellen, Caghan Kizil, Ismael Santa‐Maria
British Journal of Pharmacology.2023;[Epub] CrossRef
Midbrain area and the hummingbird sign from brain MRI in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus
Johan Virhammar, Harald Blohmé, Dag Nyholm, Charalampos Georgiopoulos, David Fällmar
Journal of Neuroimaging.2022; 32(1): 90. CrossRef
Cognitive, Psychiatric, and Motor Symptoms–Based Algorithmic Approach to Differentiate Among Various Types of Dementia Syndromes
Rehab Magdy, Mona Hussein
Journal of Nervous & Mental Disease.2022; 210(2): 129. CrossRef
Idiopathic normal pressure hydrocephalus-like MRI features in patients with progressive supranuclear palsy: a comparative case-control study
Halil Onder, Bilge Kocer, Selcuk Comoglu
Neurological Research.2022; 44(9): 807. CrossRef
Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders
M. Lopez-Cuina, W.G. Meissner
Revue Neurologique.2022; 178(5): 460. CrossRef
Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism
Hae-Won Shin, Sang-Wook Hong, Young Chul Youn
Journal of Clinical Neurology.2022; 18(3): 259. CrossRef
Dopamine transporter imaging in progressive supranuclear palsy: Severe but nonspecific to subtypes
Qi‐Si Chen, Xin‐Yi Li, Ling Li, Jia‐Ying Lu, Yi‐Min Sun, Feng‐Tao Liu, Chuan‐Tao Zuo, Jian Wang
Acta Neurologica Scandinavica.2022; 146(3): 237. CrossRef
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Kanta Horie, Nicolas R. Barthélemy, Salvatore Spina, Lawren VandeVrede, Yingxin He, Ross W. Paterson, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Celeste M. Karch, William W. Seeley, Richard J. Perrin, Rama K. Koppisetti, Faris Shaikh, Argentina L
Nature Medicine.2022; 28(12): 2547. CrossRef
Role of Multivoxel MR Spectroscopy Progressive Supranuclear Palsy – A Preliminary Study
Sandhya Mangalore, Manoj Kumar, Pramod Pal, Jitender Saini, Shaik Pasha, Ravi Yadav
Neurology India.2022; 70(6): 2388. CrossRef
Genetics of Progressive Supranuclear Palsy: A Review
Yafei Wen, Yafang Zhou, Bin Jiao, Lu Shen
Journal of Parkinson's Disease.2021; 11(1): 93. CrossRef
Disease course and treatment patterns in progressive supranuclear palsy: A real-world study
John C. Morgan, Xiaolan Ye, Jennifer A. Mellor, Keisha J. Golden, Jorge Zamudio, Louis A. Chiodo, Yanjun Bao, Tao Xie
Journal of the Neurological Sciences.2021; 421: 117293. CrossRef
Central nystagmus in progressive supranuclear palsy: A neglected clinical feature?
Maja Klarendic, Manja Hribar, Nina Bozanic Urbancic, Nina Zupancic, Milica G. Kramberger, Maja Trost, Saba Battelino, Diego Kaski, Maja Kojovic
Parkinsonism & Related Disorders.2021; 84: 15. CrossRef
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, Anwar Ahmed, Ikuko Aiba, Alberto Albanese, Kelly Bertram, Yvet
The Lancet Neurology.2021; 20(3): 182. CrossRef
A Study on the Essential and Parkinson’s Arm Tremor Classification
Vasileios Skaramagkas, George Andrikopoulos, Zinovia Kefalopoulou, Panagiotis Polychronopoulos
Signals.2021; 2(2): 201. CrossRef
Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors
Michelle Oyeka, Terngu Ibilah, Jacob Israel, Jose Gavito-Higuera, Ricardo Salazar
Cureus.2021;[Epub] CrossRef
Progressive supranuclear palsy
N.V. Fedorova, E.V. Bril, T.K. Kulua, A.D. Mikhaylova
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(5): 111. CrossRef
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care
Brent Bluett, Alexander Y. Pantelyat, Irene Litvan, Farwa Ali, Diana Apetauerova, Danny Bega, Lisa Bloom, James Bower, Adam L. Boxer, Marian L. Dale, Rohit Dhall, Antoine Duquette, Hubert H. Fernandez, Jori E. Fleisher, Murray Grossman, Michael Howell, Di
Frontiers in Neurology.2021;[Epub] CrossRef
The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes
Monica Diez-Fairen, Pilar Alvarez Jerez, Joos Berghausen, Sara Bandres-Ciga
International Journal of Molecular Sciences.2021; 22(15): 8100. CrossRef
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology
Chihiro Sato, Nipun Mallipeddi, Nupur Ghoshal, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Albert H. Kim, Gregory J. Zipfel, Randall J. Bateman, Audrey Gabelle, Nicolas R. Barthélemy
Annals of Clinical and Translational Neurology.2021; 8(9): 1817. CrossRef
“Parkinson’s disease” on the way to progressive supranuclear palsy: a review on PSP-parkinsonism
Ján Necpál, Miroslav Borsek, Bibiána Jeleňová
Neurological Sciences.2021; 42(12): 4927. CrossRef
Estimation and discussion of prognosis in neurologic practice. Communication issues with patient with neurological disease
E. V. Bril, A. V. Khasina, F. A. Abbasov, O. S. Zimnyakova, N. V. Fedorova
Medical alphabet.2021; (22): 55. CrossRef
The Progressive Supranuclear Palsy: Past and Present Aspects
Theodore P. Parthimos, Kleopatra H. Schulpis
Clinical Gerontologist.2020; 43(2): 155. CrossRef
Machine Learning Techniques to Identify Dementia
Nivedita Manohar Mathkunti, Shanta Rangaswamy
SN Computer Science.2020;[Epub] CrossRef
My dad and progressive supranuclear palsy (PSP)
Heather Angus-Leppan
Practical Neurology.2020; 20(3): 263. CrossRef
Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics
Jacky Ganguly, Mandar Jog
Frontiers in Neurology.2020;[Epub] CrossRef
A Home-Based, Music-Cued Movement Program Is Feasible and May Improve Gait in Progressive Supranuclear Palsy
Joanne E. Wittwer, Margaret Winbolt, Meg E. Morris
Frontiers in Neurology.2019;[Epub] CrossRef
Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy
Marcos C B Oliveira, Helen Ling, Andrew J Lees, Janice L Holton, Eduardo De Pablo-Fernandez, Thomas T Warner
Journal of Neurology, Neurosurgery & Psychiatry.2019; 90(5): 555. CrossRef
Revisiting the diagnostic value of Evans’ index: lessons from an unusual case of normal pressure hydrocephalus with Evans’ index less than 0.3
Jung E. Park, Hyunjin Ju, Kayeong Im, Kyum-Yil Kwon
Neurological Sciences.2019; 40(12): 2637. CrossRef
Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly
Ricardo Fernández-Ferreira, Raúl Anwar García-Santos, Mayela Rodríguez-Violante, Coral López-Martínez, Ivonne Karina Becerra-Laparra, María Eugenia Torres-Pérez
Revista Española de Geriatría y Gerontología.2019; 54(5): 251. CrossRef
Neuroinflammation as a Common Feature of Neurodegenerative Disorders
Leonardo Guzman-Martinez, Ricardo B. Maccioni, Víctor Andrade, Leonardo Patricio Navarrete, María Gabriela Pastor, Nicolas Ramos-Escobar
Frontiers in Pharmacology.2019;[Epub] CrossRef
On the journey to uncover the causes of selective cellular and regional vulnerability in neurodegeneration
Zane Jaunmuktane, Sebastian Brandner
Acta Neuropathologica.2019; 138(5): 677. CrossRef
Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study
Louise Wiblin, Rory Durcan, Brook Galna, Mark Lee, David Burn
Journal of Movement Disorders.2019; 12(3): 177. CrossRef
Prediction of the Clinical Severity of Progressive Supranuclear Palsy by Diffusion Tensor Imaging
Yao-Liang Chen, Xiang-An Zhao, Shu-Hang Ng, Chin-Song Lu, Yu-Chun Lin, Jur-Shan Cheng, Chih-Chien Tsai, Jiun-Jie Wang
Journal of Clinical Medicine.2019; 9(1): 40. CrossRef
Tauopathy with hippocampal 4‐repeat tau immunoreactive spherical inclusions: a report of three cases
Gabor G. Kovacs, Linda K. Kwong, Murray Grossman, David J. Irwin, Edward B. Lee, John L. Robinson, Eunran Suh, Vivianna M. Van Deerlin, Virginia M. Lee, John Q. Trojanowski
Brain Pathology.2018; 28(2): 274. CrossRef
A case of spinal anesthesia in a patient with progressive supranuclear palsy
Momoka Tonan, Moritoki Egi, Nana Furushima, Satoshi Mizobuchi
JA Clinical Reports.2018;[Epub] CrossRef
Is it Useful to Classify PSP and CBD as Different Disorders? Yes
Helen Ling, Antonella Macerollo
Movement Disorders Clinical Practice.2018; 5(2): 145. CrossRef
Difficulties in the diagnosis of four repeats (4R) tauopathic parkinsonian syndromes
Piotr Alster, Ewa Krzyżanowska, Dariusz Koziorowski, Stanisław Szlufik, Dorota Różański, Joanna Noskowska, Justyna Mianowicz, Adrian Michno, Leszek Królicki, Andrzej Friedman
Neurologia i Neurochirurgia Polska.2018; 52(4): 459. CrossRef
Neuro-ophthalmology of movement disorders
Olga Waln, Joseph Jankovic
Expert Review of Ophthalmology.2018; 13(5): 283. CrossRef
Role of Neuroimaging on Differentiation of Parkinson’s Disease and Its Related Diseases
Toshihide Ogawa, Shinya Fujii, Keita Kuya, Shin-ichiro Kitao, Yuki Shinohara, Mana Ishibashi, Yoshio Tanabe
Yonago Acta Medica.2018; 61(3): 145. CrossRef
Gait disorders in adults and the elderly
Walter Pirker, Regina Katzenschlager
Wiener klinische Wochenschrift.2017; 129(3-4): 81. CrossRef
Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease
Steve Vucic, Matthew C. Kiernan
Neurotherapeutics.2017; 14(1): 91. CrossRef
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
Adam L Boxer, Jin-Tai Yu, Lawrence I Golbe, Irene Litvan, Anthony E Lang, Günter U Höglinger
The Lancet Neurology.2017; 16(7): 552. CrossRef

First
Prev
Page of 1
Next
Last

Search